Evidence map›Paper›PMID 27208115›Full record

ArticleApplied and environmental microbiology2016

Pichia pastoris Exhibits High Viability and a Low Maintenance Energy Requirement at Near-Zero Specific Growth Rates.

Corinna Rebnegger, Tim Vos, Alexandra B Graf, Minoska Valli, Jack T Pronk, Pascale Daran-Lapujade, Diethard Mattanovich

Abstract read
In one paragraph

Article in Applied and environmental microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Anti-Oxidative and Anti-Apoptotic Oligosaccharides fromPharmaceuticals (Basel, Switzerland) · 2024
    Article
  11. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Enabling growth-decoupledFrontiers in bioengineering and biotechnology · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Selective Eradication ofAntibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Corinna RebneggerDepartment of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, Austria.
Tim VosDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.
Alexandra B GrafSchool of Bioengineering, University of Applied Sciences FH Campus Vienna, Vienna, Austria.
Minoska ValliDepartment of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, Austria.
Jack T PronkDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.
Pascale Daran-LapujadeDepartment of Biotechnology, Delft University of Technology, Delft, The Netherlands.ORCID http://orcid.org/0000-0002-4097-7831
Diethard MattanovichDepartment of Biotechnology, BOKU-University of Natural Resources and Life Sciences, Vienna, Austria diethard.mattanovich@boku.ac.at.

Funding

Austrian Science Fund FWF W 1224
6 · The paper itself

Abstract

unlabelledThe yeast Pichia pastoris is a widely used host for recombinant protein production. Understanding its physiology at extremely low growth rates is a first step in the direction of decoupling product formation from cellular growth and therefore of biotechnological relevance. Retentostat cultivation is an excellent tool for studying microbes at extremely low specific growth rates but has so far not been implemented for P. pastoris Retentostat feeding regimes were based on the maintenance energy requirement (mS) and maximum biomass yield on glucose (YX /S (max)) estimated from steady-state glucose-limited chemostat cultures. Aerobic retentostat cultivation enabled reproducible, smooth transitions from a specific growth rate (μ) of 0.025 h(-1) to near-zero specific growth rates (μ < 0.001 h(-1)). At these near-zero specific growth rates, viability remained at least 97%. The value of mS at near-zero growth rates was 3.1 ± 0.1 mg glucose per g biomass and h, which was 3-fold lower than the mS estimated from faster-growing chemostat cultures. This difference indicated that P. pastoris reduces its maintenance energy requirement at extremely low μ, a phenomenon not previously observed in eukaryotes. Intracellular levels of glycogen and trehalose increased, while μ progressively declined during retentostat cultivation. Transcriptional reprogramming toward zero growth included the upregulation of many transcription factors as well as stress-related genes and the downregulation of cell cycle genes. This study underlines the relevance of comparative analysis of maintenance energy metabolism, which has an important impact on large-scale industrial processes. IMPORTANCE: The yeast Pichia pastoris naturally lives on trees and can utilize different carbon sources, among them glucose, glycerol, and methanol. In biotechnology, it is widely used for the production of recombinant proteins. For both the understanding of life in its natural habitat and optimized production processes, a better understanding of cell physiology at an extremely low growth rate would be of extraordinary value. Therefore, we have grown P. pastoris in a retentostat, which allows the cultivation of metabolically active cells even at zero growth. Here we reached doubling times as long as 38 days and found that P. pastoris decreases its maintenance energy demand 3-fold during very slow growth, which enables it to survive with a much lower substrate supply than baker's yeast.

Indexed as

Energy MetabolismBiomassFungal ProteinsGlucoseGlycerolKineticsMethanolPichiaTranscription FactorsTrehaloseFungal ProteinsGlucoseGlycerolMethanolTranscription FactorsTrehalose

Identifiers

PMID27208115
PMCPMC4984280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.